Certain patients with germ cell cancer should receive life-long follow-up
the ONA take:
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death, and therefore should be candidates for life-long follow-up care, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers identified 268 patients with germ cell cancer who received more than one line of treatment for disseminated disease from the Danish Testicular Cancer database to evaluate late toxicity and survival.
Results showed that just more than half of patients died from germ cell cancer. The remaining patients had an increased risk for developing a second cancer, major cardiovascular disease, pulmonary disease, gastrointestinal disease, renal impairment, neurologic disorders, and death from other causes compared with patients who only underwent orchiectomy.
Researchers found that increasing age may contribute to treatment failure after second-line treatment in these patients.
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|